Lui Franciosi To Monitor the Safety and Efficacy of Nebulized Heparin for the Treatment of COVID-19
January 06, 2022 12:00 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e., COVID-19. There is...
Acute Respiratory Distress Syndrome Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
December 22, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
September 30, 2021 07:00 ET
|
Trevena Inc.
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average...
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 20, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET
|
Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
April 21, 2021 07:00 ET
|
Trevena Inc.
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data...
Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
April 20, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.All 10 patients were discharged from hospital within three days after their last COVI-MSC...
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
March 25, 2021 15:58 ET
|
Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
March 25, 2021 00:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...